Navigation Links
Abbott's XIENCE(TM) V Drug Eluting Stent Demonstrates Consistent and Positive Clinical Outcomes Out to Two Years
Date:3/31/2008

- New Data from SPIRIT II Show Continued Low Rates of MACE with XIENCE V -

CHICAGO, March 31 /PRNewswire-FirstCall/ -- Data presented today from Abbott's SPIRIT II clinical trial demonstrated continued positive clinical results for the XIENCE(TM) V Everolimus Eluting Coronary Stent System out to two years, including an observed 40 percent reduction in major adverse cardiac events (MACE) and an observed 44 percent reduction in vessel retreatment (ischemia-driven target lesion revascularization, TLR) compared to the TAXUS(R) paclitaxel-eluting coronary stent system. The two-year results from the SPIRIT II trial were presented at the SCAI Annual Scientific Sessions in Partnership with ACC i2 Summit.

SPIRIT II is a 300-patient randomized clinical trial, which was conducted in Europe and Asia Pacific to support the launch of XIENCE V outside the United States. In SPIRIT II, XIENCE V demonstrated the following key results:

-- In an analysis of major adverse cardiac events (MACE), XIENCE V

demonstrated an observed 40 percent reduction in MACE compared to

TAXUS at two years (6.6 percent for XIENCE V vs. 11.0 percent for

TAXUS). MACE is an important clinical measure of patient outcomes,

defined as cardiac death, heart attack (myocardial infarction or MI),

or ischemia-driven target lesion revascularization.

-- XIENCE V demonstrated an observed 44 percent reduction in

ischemia-driven target lesion revascularization (TLR driven by lack of

blood supply) compared to TAXUS at two years (3.8 percent for XIENCE V

vs. 6.8 percent for TAXUS).

-- Rates of definite/probable stent thrombosis under the Dublin/Academic

Research Consortium (ARC) definition were 0.9 percent for XIENCE V and

1.4 percent for TAXUS at two years. The ARC definition of late-stent

thrombosis was developed to eliminate variability in the definitions

across various
'/>"/>

SOURCE Abbott
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Abbotts XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
2. Spirit II Results Support Strength of Boston Scientifics Two Drug-Eluting Stent Platforms
3. Large Study Gives Nod to Drug-Eluting Stents in Heart Attack
4. Drug-Eluting Stents Outperform Bare Stents in Heart Attack
5. Abbott Announces Positive One-Year Results from the Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
6. XTENT Announces Positive Two-Year CUSTOM I and One-Year CUSTOM II Trial Data for Novel Drug-Eluting Stent System
7. Four Analyses of Three-Year Clinical Data Suggest CYPHER(R) Sirolimus-Eluting Coronary Stent May Provide Alternative to Surgery for Patients with Multivessel Disease
8. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
9. Largest Study to Date Shows Significant Reductions in Risks of Blood Clots and Reintervention With CYPHER(R) Sirolimus-eluting Coronary Stent Compared to Taxus Stent
10. Two-Year Outcomes From Large Head-to-Head Clinical Trial Indicate Similar Safety Profile in Diabetic Patients for Cypher(R) Sirolimus-Eluting Coronary Stent and Taxus Stent
11. Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... England and BOSTON , ... GPCR drug discovery and development company, is pleased to announce that ... a Consultant to augment the Company,s business development capabilities in ... Usui has more than 15 years of experience in business development, ... at Perlegen Sciences, Inc., Roche Pharma ( Japan ), ...
(Date:5/23/2013)... , May 24, 2013 3SBio ... the "Company"), a leading China ... and marketing biopharmaceutical products, announced today that, at ... the Company,s shareholders voted in favor of the ... agreement and plan of merger dated February 8, ...
(Date:5/23/2013)... WASHINGTON , May 23, 2013  Vanda Pharmaceuticals Inc. ... company has been named the 2013 Life Science Firm of ... (TCM).  Vanda was honored at the TCM,s 25 ... Bethesda , Maryland.  The Tech Awards Celebration recognizes the ... in Maryland and the surrounding regions. ...
Breaking Medicine Technology:Heptares Augments Business Development Capabilities in Japan and Other Asian Territories 23SBio Inc. Announces Shareholders' Approval of the Amended Merger Agreement 23SBio Inc. Announces Shareholders' Approval of the Amended Merger Agreement 3Vanda Pharmaceuticals Named the 2013 Life Science Firm of the Year by the Tech Council of Maryland 2
... Oct. 29 /PRNewswire-FirstCall/ -- ... the global specialty biopharmaceutical company, announced today that it will ... INTUNIV (TM) (guanfacine) Extended Release Tablets, ... Daytrana ®( ) (methylphenidate transdermal system) CII, ...
... Matrox Graphics Inc., the leading manufacturer of specialized graphics ... the Matrox Xenia(TM) display controller boards ... workstations . The software suite contains a number ... including Radiology Information System (RIS), Picture Archiving and Communication ...
Cached Medicine Technology:Shire to Present Important Study Findings on its ADHD Treatments at a Major Psychiatric Meeting on October 29 and 30 2Shire to Present Important Study Findings on its ADHD Treatments at a Major Psychiatric Meeting on October 29 and 30 3Shire to Present Important Study Findings on its ADHD Treatments at a Major Psychiatric Meeting on October 29 and 30 4Shire to Present Important Study Findings on its ADHD Treatments at a Major Psychiatric Meeting on October 29 and 30 5Shire to Present Important Study Findings on its ADHD Treatments at a Major Psychiatric Meeting on October 29 and 30 6Shire to Present Important Study Findings on its ADHD Treatments at a Major Psychiatric Meeting on October 29 and 30 7Shire to Present Important Study Findings on its ADHD Treatments at a Major Psychiatric Meeting on October 29 and 30 8Shire to Present Important Study Findings on its ADHD Treatments at a Major Psychiatric Meeting on October 29 and 30 9Rogan-Delft Approves Matrox Xenia Series for Use With Zillion Suite 2Rogan-Delft Approves Matrox Xenia Series for Use With Zillion Suite 3
(Date:5/23/2013)... 24, 2013 Magnatag’s new magnetic 365-Day ... and reduces vacation conflicts. A Manufacturing Manager from Augusta ... conflicts; now employees and managers can check the board ... Attendance is important to us and the board makes ... may seem harsh but it has made a difference.” ...
(Date:5/23/2013)... Over the past decade, the traditional ... has affected the Medical Group Practice Management industry ... hours, more young physicians are opting out of private ... says IBISWorld industry analyst Anna Son. In addition, “faced ... of older physicians are selling their practices and moving ...
(Date:5/23/2013)... (PRWEB) May 24, 2013 Sublime ... Cellulite Whisperer line, with a 35% ... Summer Sale" includes two proprietary products, the ... Lotion . , Purchasers receive a report "Getting ... "The Gel has a wonderful grapefruit scent," says ...
(Date:5/23/2013)... HI (PRWEB) May 23, 2013 Magic often ... book describing the exploits of precocious twin five-year olds, Howie ... , is just such a case in point. May 23, ... and is timed to coincide with the start of ... experience combining family adventures, tons of amenities and, most precious ...
(Date:5/23/2013)... May 24, 2013 -- High blood glucose is associated ... intensive insulin therapy (IIT) to control hyperglycemia is a ... not show a consistent benefit and even shows harms ... American College of Physicians, (ACP) Clinical Guidelines Committee in ... American Journal of Medical Quality . , "Clinicians ...
Breaking Medicine News(10 mins):Health News:New Attendance, Vacation and Training Tracker Board Reduces Employee Conflicts and Improves Attendance 2Health News:Medical Group Practice Management in the US Industry Market Research Report Now Available from IBISWorld 2Health News:Medical Group Practice Management in the US Industry Market Research Report Now Available from IBISWorld 3Health News:Fresh Organics in the New Cellulite Whisperer® Products from Sublime Beauty®; "Get Ready for Summer Sale" Continues 2Health News:New Children's Comic Book, "Howie Goes to Maui," Launches May 23, 2013 On Four Seasons Resort Maui's Web Site 2Health News:New Children's Comic Book, "Howie Goes to Maui," Launches May 23, 2013 On Four Seasons Resort Maui's Web Site 3Health News:ACP issues recommendations for management of high blood glucose in hospitalized patients 2
... Colon cleansing is used widely for colonoscopic exploration ... (OSP) solution is the osmotic laxative most commonly ... OSP can induce severe hyperphosphatemia and hypocalcemia due ... been reports of deaths and irreversible dialysis-requiring renal ...
... is increasing worldwide and its prognosis is very ... for early detection and on surgical treatment for ... research team from China retrospectively evaluated 5311 liver ... and December 2003. Of these, 429 (8.1%) patients ...
... ... will be speaking at the McGuire Woods LLP "7th Annual Healthcare and Life ... 11, 2010 at the Palmer House Hilton in Chicago. Mr. Lynch will ... revenues in healthcare services. , ...
... ... The United States Department of Justice filed a complaint ... Johnson committed Medicaid fraud by paying Omnicare pharmacies kickbacks for recommending ... drugs. Omnicare is the largest pharmacy supplying drugs to nursing ...
... emergency department, federal report shows , THURSDAY, Jan. 14 ... million motor vehicle crash victims who had injuries ranging ... a new government study finds. , About 85 percent ... 321,000 were admitted or transferred to another acute care ...
... ... Scantronix’ Paper Medical Chart Conversions to all ePaperless Solutions’ EMR System Clients on the ... ... 15, 2010 -- Scantronix.net, an industry leader in electronic medical record (EMR) scanning, digitization ...
Cached Medicine News:Health News:Anesthesia Healthcare Partners CEO to Speak at Upcoming Healthcare Conference to Offer Insight on Managing Costs in Healthcare Services 2Health News:U.S. Department of Justice Alleges Johnson & Johnson Paid Kickbacks to Steer Nursing Home Prescriptions: Joins Chicago Pharmacist's Whistleblower Case 2Health News:U.S. Department of Justice Alleges Johnson & Johnson Paid Kickbacks to Steer Nursing Home Prescriptions: Joins Chicago Pharmacist's Whistleblower Case 3Health News:U.S. Department of Justice Alleges Johnson & Johnson Paid Kickbacks to Steer Nursing Home Prescriptions: Joins Chicago Pharmacist's Whistleblower Case 4Health News:U.S. Department of Justice Alleges Johnson & Johnson Paid Kickbacks to Steer Nursing Home Prescriptions: Joins Chicago Pharmacist's Whistleblower Case 5Health News:Scantronix and ePaperlessSolutions Form Key Partnership 2Health News:Scantronix and ePaperlessSolutions Form Key Partnership 3
... a fully automated genetic analysis system. This ... a patented linear polyacrylamide (LPA) gel, denatures ... program, and analyzes the data. Software tools ... even customize automated data assessment. All to ...
Basic critical care testing. Measures pH, pCO2, and pO2 from 85 L whole-blood sample....
... Measures up to 17 parameters ... blood: pH and blood gases, as ... bilirubin, electrolyte, and metabolite parameters. Unique ... interfering effect some substances have on ...
348 is fully automated blood gas systems offering a cost-effective solution for critical care testing in settings with low to medium workloads....
Medicine Products: